Press Releases
Date Title and Summary View
May 9, 2012 NEW HAVEN, Conn., May 9, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that it has begun dosing ACH-3102 in a Phase 1 clinical trial. ACH-3102 is Achillion's second generation pan-genotypic NS5A inhibitor being investigated for the treatment of chronic hepatitis C virus (HCV) infection. ACH-3102 is a str...
Apr 23, 2012 NEW HAVEN, Conn., April 23, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today provided clarification with respect to end of treatment (EOT) data from segment 2 of its Phase 2a trial of ACH-1625 that was presented during the 47th Annual Meeting of the European Association for the Study of the Liver (EASL) International Liv...
Apr 21, 2012 NEW HAVEN, Conn., April 21, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that in the second segment of its Phase 2a trial of ACH-1625, 94 to 100 percent of patients with treatment naïv...
Mar 8, 2012 NEW HAVEN, Conn., March 8, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three and twelve months ended December 31, 2011. For the three months ended December 31,...
Mar 2, 2012 NEW HAVEN, Conn., March 2, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that it plans to release fourth quarter and full year 2011 financial results on Thursday, March 8, 2012, before the m...
Mar 1, 2012 NEW HAVEN, Conn., March 1, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that members of the executive team will provide a corporate update at the following upcoming investor conferences: ...
Feb 16, 2012 NEW HAVEN, Conn., Feb. 16, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that novel preclinical and clinical virology data on ACH-1625, a Phase 2 pan-genotypic protease inhibitor, was presen...
Feb 8, 2012 NEW HAVEN, Conn., Feb. 8, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael Kishbauch, President and Chief Executive Officer of Achillion, will provide a corporate update at the fol...
Feb 3, 2012 NEW HAVEN, Conn., Feb. 3, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the promotion of Mr. Joseph Truitt to Senior Vice President of Business Development. Mr. Truitt maintains his position...
Jan 13, 2012 NEW HAVEN, Conn., Jan. 13, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Joseph Truitt, Senior Vice President of Business Development and Chief Commercial Officer of Achillion, will pre...
FirstPrevious ...
7
... NextLast
Add to Briefcase = add release to Briefcase

built@zoomedia
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue